Company Overview of Organovo Holdings, Inc.
Organovo Holdings, Inc., an early commercial stage company, focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. It is developing a suite of standardized and three-dimensional human tissues for the preclinical assessment of drug effects, including applications in predictive toxicology, absorption, distribution, metabolism, excretion, and drug metabolism and pharmacokinetics; customized human tissues as living, dynamic models of human biology or disease for use in drug discovery and development; and three-dime...
6275 Nancy Ridge Drive
San Diego, CA 92121
Founded in 2007
Key Executives for Organovo Holdings, Inc.
Chairman, Chief Executive Officer, President and Principal Accounting Officer
Total Annual Compensation: $499.1K
Chief Scientific Officer and President of Samsara
Total Annual Compensation: $349.5K
Chief Strategy Officer and Executive Vice President of Preclinical Development
Total Annual Compensation: $324.6K
Compliance Officer, General Counsel and Corporate Secretary
Total Annual Compensation: $343.1K
Total Annual Compensation: $344.7K
Compensation as of Fiscal Year 2016.
Organovo Holdings, Inc. Key Developments
Organovo Holdings Signs Exclusive Distributor Agreement with Cosmo Bio Co., Ltd
Dec 14 16
Organovo Holdings, Inc. announced an exclusive distributor agreement with Cosmo Bio Co. Ltd. for its NovoView Preclinical Services in Japan. Organovo will work with CosmoBio’s Drug Discovery Services (DDS) team to gain direct access to customers and support projects throughout the Japanese biopharmaceutical industry.
Organovo Holdings, Inc Announces First Preclinical Data on 3D Bioprinted Human Liver Tissues
Dec 13 16
Organovo Holdings, Inc. is presenting the first data showing survival and sustained functionality of its 3D bioprinted human liver tissue when implanted into animal models. This data is being presented at the TERMIS-Americas Meeting in San Diego. Organovo implanted its 3D bioprinted human liver tissue patches onto the livers of NOD/SCID mice. The tissue was composed of human hepatocytes and select non-parenchymal cells. Function of the 3D bioprinted human liver tissue patches was seen via detection of human albumin, alpha-1-anti-trypsin and fibrinogen in the circulating blood of the mice as early as seven days and for at least 28 days post-implantation. Histopathologic evaluation of the implanted therapeutic tissue revealed retention of the bioprinted cellular organization through 28 days post-implantation, with robust staining for key human metabolic enzymes associated with inborn errors of metabolism, such as Fumarylacetoacetate Hydrolase (FAH) deficiency and Ornithine Transcarbamylase (OTC) deficiency. The tissues remained intact on the animal liver and were well tolerated by the animals. Taken together, these data support further preclinical development of Organovo’s 3D bioprinted liver tissue for therapeutic use. Focusing first on acute-on-chronic liver failure and pediatric inborn errors of metabolism, both indications where a bioprinted liver patch may show therapeutic benefits, Organovo intends to submit an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) for its therapeutic liver tissue in three to five years.
Organovo Holdings, Inc. Presents at Virtual Investor Conference, Dec-13-2016 01:00 PM
Dec 8 16
Organovo Holdings, Inc. Presents at Virtual Investor Conference, Dec-13-2016 01:00 PM. Speakers: Keith Murphy, Chairman, Chief Executive Officer, President and Principal Accounting Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|